

11th Northeast Regional Hematology/Oncology Pharmacists Symposium

Boston Marriott Burlington Hotel & Conference Center

One Burlington Mall Road, Burlington, MA 01803
781-229-6565

October 13 & 14, 2017

- Earn up to 13 Contact Hours (1.3 CEUs) Including 2 hours of Law and 1 hour Sterile Compounding
- 16 individually accredited sessions for Pharmacists & Nurses
- Network with industry professionals
- Breakfast, lunch, welcome cocktail reception and dinner
- Don't miss the 4 industry sponsored non CE presentations

Educational Sponsor:



Association Sponsors:



Supported by Educational Grants from:

Celgene Corporation
Takeda Oncology
Bristol-Myers Squibb

Promotional Sponsors:

Platinum: Eisai, Inc., Amgen

Gold: Takeda

Silver: Janssen Oncology, Lilly, Merck

Bronze: Pfizer Oncology

A decorative graphic at the bottom of the page featuring stylized human figures in various poses, rendered in a light blue color.

Friday, October 13, 2017

9:00 a.m. - 9:40 a.m. Registration & Exhibitor Pavilion
 9:40 a.m. - 9:50 a.m. Opening Remarks
 9:50 a.m. - 10:50 a.m. Utilizing Pharmacogenomics to Personalize Oncology Drug Therapy
 11:00 a.m. - 12:00 p.m. Implementing Cancer Genomics into Clinical Practice
 12:00 p.m. - 1:00 p.m. Buffet Lunch, Exhibitor Pavilion
 1:05 p.m. - 2:05 p.m. Where Do We Stand With Biosimilars: A 2017 Update (Law Credit)
 2:05 p.m. - 2:30 p.m. Refreshments, Exhibitor Pavilion
 2:30 p.m. - 3:30 p.m. Therapy Selection in Myeloma Patients with Comorbidities
 2:30 p.m. - 3:30 p.m. Concurrent session: Managing of Venous Thromboembolism in the Oncology Patient
 3:30 p.m. - 4:00 p.m. Refreshments, Exhibitor Pavilion
 4:00 p.m. - 5:00 p.m. Expanding Options for Treatment in Chronic Lymphocytic Leukemia (CLL): The Wheel is Turning and it Can't Slow Down
 5:00 p.m. - 6:00 p.m. Welcome Reception for Attendees and Exhibitors
 6:00 p.m. - 7:00 p.m. Buffet Dinner
 7:00 p.m. - 8:00 p.m. Update in the Treatment of Genitourinary Cancer

Saturday, October 14, 2017

7:00 a.m. - 7:45 a.m. Registration & Buffet Breakfast
 7:45 a.m. - 8:45 a.m. A Review of New and Emerging Treatments for AML
 9:00 a.m. - 10:00 a.m. Balancing Benefit and Risk in Patients with Early Stage and Locally Advanced Breast Cancer: How Much Is Too Much?
 9:00 a.m. - 10:00 a.m. Concurrent session: Current Trends in Supportive Oncology: CINV and Early Palliative Care
 10:00 a.m. - 10:15 a.m. Refreshments, Exhibitor Pavilion
 10:15 a.m. - 11:15 a.m. Precision Medicine in Non-Small Cell Lung Cancer: Focus on the Role of Targeted Therapies
 10:15 a.m. - 11:15 a.m. The Emerging Role of CAR-T-Cell Therapy in the Treatment of Hematological Malignancies
 11:15 a.m. - 11:30 p.m. Refreshments, Exhibitor Pavilion
 11:30 a.m. - 12:30 p.m. The 411 on the Challenges in the Treatment of Ovarian Cancer
 12:30 p.m. - 1:30 p.m. Buffet Lunch
 1:30 p.m. - 2:30 p.m. Melanoma: Finding the KEY and CHECKING for Best COMBI Therapy
 2:35 p.m. - 3:35 p.m. Sarcomas from Caveman to Modern Man
 3:40 p.m. - 4:40 p.m. Improving the Safety of Compounded Preparations – FDA, <USP 797 & 800>, & State Regulations: Finding Balance within Prevailing Regulation (Law credit + Sterile Compounding)

Credits: Earn up to 13 Contact Hours (1.3 CEUs). Additional information on our website.

Cost: 2 Days: \$130 Members* 1-Day: \$100 Members*
 \$150 Non-members \$115 Non-members

*MSHP, ONS NH/VT, ONS Boston, HOPA, DFCI

Fee includes credits, handouts plus breakfast, lunches, all day refreshments, welcome cocktail reception, and dinner.

Overnight Room Reservations: Secure your reservations by 9/28/17. Call 888-855-7741 and mention code "NEHOPS" for a special rate of \$169.00/night. On-line registration at www.burlingtonmarriott.com



Ms. Mr. Pharmacist Nurse Other

Member _____ Lic # _____

NABP e-profile # _____ Birth Date: MM/DD _____

Name _____

Home Address _____

City _____ State _____ Zip _____

Tel. _____

Email _____

Employer Name _____

Practice Setting: Health Systems/Hospital Community/Retail MC
 Specialty LTC Academic Other

PAYMENT INFORMATION

Check or Money Order made payable to: American Health Resources, Inc.
 Charge my Credit Card Visa MC AmEx Discover

Acct. # _____ CVC _____

Expiration _____ Signature _____

~ Register by Mail, Fax, Internet or Phone ~

American Health Resources, Inc., 130 Liberty St., Suite 13A, Brockton, MA 02301
 Tel. 508-588-7700 • Fax 508-588-7701 • www.AHRevents.com

Opening Remarks • 9:40 a.m. – 9:50 a.m.

Seminar 1 • 9:50 a.m. – 10:50 a.m.

Utilizing Pharmacogenomics to Personalize Oncology Drug Therapy

Presenter: Cyrine-Eliana Haidar, Pharm.D., BCPS, BCOP; Clinical Pharmacogenetics Coordinator, St. Jude Children's Research Hospital, Memphis, TN

Learning Objectives:

- Summarize the difference between germline and somatic genetic testing.
- Discuss the pharmacogenes that are important in oncology.
- Describe an example of pharmacogenomic implementation in an oncology setting.
- Discuss and identify the pharmacogenomic educational resources.

ACPE UPN: 0280-0000-17-065-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 2 • 11:00 a.m. – 12:00 p.m.

Implementing Cancer Genomics into Clinical Practice

Presenter: Casey Williams, Pharm.D., BCOP, FHOPA; VP, Department of Molecular and Experimental Medicine, Clinical Associate Professor, University of South Dakota School of Medicine; Adjunct Clinical Associate Professor, University of Kansas School of Pharmacy; Adjunct Clinical Associate Professor, South Dakota State University School of Pharmacy

Learning Objectives:

- Describe current state of the art of cancer genomics.
- Discuss challenges of implementing precision oncology in clinical practice.
- Summarize literature around combining multiple therapeutic agents.
- Discuss current understanding of the costs of cancer genomics and strategies to reduce barriers to care.

ACPE UPN: 0280-0000-17-066-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 3 • 1:05 p.m. – 2:05 p.m.

Where Do We Stand With Biosimilars: A 2017 Update (Law Credit)

Presenter: Jim Koeller, MS; Professor, University of Texas at Austin & The Health Science Center, San Antonio, TX

Learning Objectives:

- Describe the science behind biologic and biosimilar manufacturing and commercialization.
- List 3 key factors for biosimilars that will allow for therapeutic interchange in your institution.
- List 3 of the most recent FDA guidance's on biosimilars and how they may affect use in your institution.
- List the current FDA approved biosimilars and explain what their impact on the US market has been.
- Describe the current biosimilar pipeline and what products we can expect out in the next year or so.

ACPE UPN: 0280-0000-17-067-L03-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 4 • 2:30 p.m. – 3:30 p.m. (Concurrent sessions)

4A Therapy Selection in Myeloma Patients with Comorbidities

Presenter: R. Donald Harvey, Pharm.D., FCCP, BCOP; Associate Professor, Hematology/Medical Oncology, Director, Phase 1 Clinical Trials Section, Winship Cancer Institute of Emory University

Learning Objectives:

- Recognize treatment-related adverse events associated with new drug regimens used to treat patients with multiple myeloma.
- Identify comorbid conditions and overlapping drug toxicities that warrant pharmacotherapeutic intervention in patients with multiple myeloma.
- Outline pharmacotherapeutic strategies for managing adverse events in comorbid patients with multiple myeloma.

ACPE UPN: 0280-0000-17-068-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 4b • 2:30 p.m. – 3:30 p.m. (Concurrent sessions)

Managing of Venous Thromboembolism in the Oncology Patient

Presenter: Jean M. Connors, MD Brigham and Women's Hospital, Department of Medicine, Hematology Division; Assistant Professor, Harvard Medical School; Director, Brigham and Women's Hospital Anticoagulation Management Service; Director, Dana-Farber Cancer Institute Anticoagulation Management Service; Director, Dana-Farber Cancer Institute Hemostatic Antithrombotic Stewardship

Learning Objectives:

- Describe factors associated with elevated VTE risk in cancer patients
- Discuss current treatment strategies for the prevention and management of cancer-associated thrombosis
- Summarize clinical safety and efficacy data on novel oral anticoagulants in the setting of venous thromboembolism and cancer

ACPE UPN: 0280-9999-17-097-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Jointly Sponsored by Dana-Farber Cancer Institute

Seminar 5 • 4:00 p.m. – 5:00 p.m.

Expanding Options for Treatment in Chronic Lymphocytic Leukemia (CLL): The Wheel is Turning and it Can't Slow Down

Presenter: Christopher A. Fausel, Pharm.D., M.H.A., BCOP; Clinical Manager, Oncology Pharmacy, Indiana University Health; Chairman of the Board, Hoosier Cancer Research

Learning Objectives:

- Describe the impact of age, comorbidities and cytogenetics on the management of CLL.
- Discuss state of the art clinical trial data for efficacy and toxicity of new and emerging therapeutic options for the management of CLL in the front-line, salvage and maintenance settings.
- Articulate general strategies to manage supportive care and address adherence for new oral targeted agents.

ACPE UPN: 0280-0000-17-069-L01-P Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 6 • 7:00 p.m. - 8:00 p.m.

Update in the Treatment of Genitourinary Cancer

Presenter: Adam Peele, Pharm.D., M.H.A., BCPS, BCOP; System Oncology Pharmacy Manager, PGY2 Oncology Pharmacy Residency Director, Cone Health, Greensboro, NC

Learning Objectives:

- Recognize the incidence and prevalence of genitourinary malignancies.
- Discuss chemotherapy options for the treatment of genitourinary malignancies.
- Evaluate the role of immuno-oncology in treating genitourinary malignancies.
- Discuss current guideline based recommendations.

ACPE UPN: 0280-0000-17-070-L01-P Application Based Credits: 1.0 Contact Hour (0.10 CEU)

Saturday, October 14, 2017

Seminar 7 • 7:45 a.m. - 8:45 a.m.

A Review of New and Emerging Treatments for AML

Presenter: Ali McBride, Pharm.D., M.S., BCPS, BCOP, Clinical Coordinator Hematology/Oncology, The University of Arizona Cancer Center, Tucson, AZ

Learning Objectives:

- Summarize molecular targets in the treatment of AML.
- Evaluate the use of Flt-3 in AML patients for treatment.
- Describe new agents in the treatment of AML.

ACPE UPN: 0280-0000-17-071-L01-P Application Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 8 • 9:00 a.m. - 10:00 a.m. (Concurrent sessions)

8A Balancing Benefit and Risk in Patients with Early Stage and Locally Advanced Breast Cancer:

How Much Is Too Much?

Presenter: Chad Barnett, Pharm.D., BCOP; Clinical Pharmacy Specialist - Breast Oncology, Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, Texas

Learning Objectives:

- Classify a breast cancer patient as a candidate for neoadjuvant or adjuvant therapies.
- Summarize the data supporting systemic therapy options for patients with early-stage and locally-advanced breast cancer.
- Recall the toxicities associated with therapeutic agents utilized in patients with early-stage and locally-advanced breast cancer.

ACPE UPN: 0280-0000-17-072-L01-P Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 8 • 9:00 a.m. - 10:00 a.m. (Concurrent sessions)

8B Current Trends in Supportive Oncology: CINV and Early Palliative Care

Presenter: Bridget Scullion, PharmD, BCOP Director of Clinical Pharmacy Services Dana-Farber Cancer Institute

Learning Objectives:

- Identify key changes in recent CINV guideline updates that impact an oncology patient's plan of care.
- Discuss the role of early palliative care in oncology and efforts to identify patient factors for implementation.

ACPE UPN: 0280-9999-17-078-L01-P Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Jointly Sponsored by Dana-Farber Cancer Institute

Seminar 9 • 10:15 a.m. - 11:15 a.m. (Concurrent sessions)

Precision Medicine in Non-Small Cell Lung Cancer: Focus on the Role of Targeted Therapies

Presenter: Val R. Adams, Pharm.D., BCOP, FCCP; Associate Professor, Pharmacy, Program Director PGY2, Specialty Residency, Hematology/Oncology, University of Kentucky College of Pharmacy, Lexington, KY

Learning Objectives:

- Identify the pros and cons of liquid biopsies when it comes to identifying driver mutations to select drug therapy.
- Discuss the most recent clinical data in first and second line treatment with a targeted therapy so that the benefits and place in therapy can be discussed with patients and healthcare providers.
- Describe common and unique toxicities associated with targeted therapies to optimize monitoring and patient counseling.

ACPE UPN: 0280-0000-17-073-L01-P Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 9b • 10:15 a.m. - 11:15 a.m. (Concurrent sessions)

The Emerging Role of CAR-T-Cell Therapy in the Treatment of Hematological Malignancies

Presenter: Caron A. Jacobson, M.D., Assistant Professor in Medicine, Harvard Medical School; Clinical Director of the Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute

Learning Objectives:

- Describe the mechanism of action of chimeric antigen receptor T-Cell (CAR-T) therapies.
- Recognize the emerging role of CAR T-cell treatment.
- Summarize current clinical trial data and describe where CAR-T cell therapies fit in the treatment landscape.
- Discuss safety and the management of potential adverse effects of CAR-T cell therapy.

ACPE UPN: 0280-9999-17-095-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Jointly Sponsored by Dana-Farber Cancer Institute

Seminar 10 • 11:30 a.m. - 12:30 p.m.

The 411 on the Challenges in the Treatment of Ovarian Cancer

Presenter: Judith A. Smith, Pharm.D., BCOP, CPHQ, FCCP, FISOPP; Associate Professor, Director, WHIM Research Program, Women's Health Integrative Medicine Research Program, Department of Obstetrics, Gynecology, & Reproductive Science, UHealth, McGovern Medical School

Learning Objectives:

- Summarize the challenges in the diagnosis and overall prognosis of ovarian cancer.
- Recognize the current role of intraperitoneal chemotherapy for the treatment of ovarian cancer.
- Discuss the evolution and limitations of targeted therapy being integrated into the treatment of advanced ovarian
- Review the prevention and management of common disease and treatment complications observed in advanced ovarian cancer patients.

ACPE UPN: 0280-0000-17-074-L01-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 11 • 1:30 p.m. - 2:30 p.m.

Melanoma: Finding the KEY and CHECKing for Best COMBI Therapy

Presenter: LeAnn B. Norris, Pharm.D., BCPS, BCOP; Associate Professor, South Carolina College of Pharmacy, University of South Carolina

Learning Objectives:

- Discuss recent updates in the treatment of melanoma.
- Identify treatment options in patients with metastatic melanoma and brain metastases.
- Evaluate the role of newer combination therapies.

ACPE UPN: 0280-0000-17-075-L01-P

Application Based Credits: 1.0 Contact Hour (0.10 CEU)

Seminar 12 • 2:35 p.m. - 3:35 p.m.

Sarcomas from Caveman to Modern Man

Presenter: Christy S. Harris, PharmD, BCPS, BCOP Associate Professor, Pharmacy Practice MCPHS University – Boston; Clinical Pharmacist, Center for Bone and Soft Tissue Sarcoma Dana-Farber Cancer Institute

Learning Objectives:

- Identify the population of patients at risk for the development of various sarcomas.
- Compare and contrast new agents for the treatment of sarcomas.
- Describe the future direction of treatment in sarcomas.

ACPE UPN: 0280-9999-17-076-L01-P

Application Based Credits: 1.0 Contact Hour (0.10 CEU)

Jointly Sponsored by Dana-Farber Cancer Institute

Seminar 13 • 3:40 p.m. - 4:40 p.m.

Improving the Safety of Compounded Preparations – FDA, <USP 797 & 800>, & State Regulations: Finding Balance within Prevailing Regulation (Law credit + Sterile Compounding)

Presenter: Lou Diorio, RPh, FAPhA, Principal, LDT Health Solutions, Inc., Wayne, NJ

Learning Objectives:

- Describe the current landscape of overlapping regulations that have an impact on compounding operations.
- Describe the environmental control requirements for sterile and/or non-sterile compounding.
- Outline strategies for managing the increasingly complex regulated environment while providing optimal patient care.

ACPE UPN: 0280-0000-17-077-L03-P

Knowledge Based Credits: 1.0 Contact Hour (0.10 CEU)



American Health Resources, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Nurses: American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 1.0 contact hour for each 1 hour session completed. Please check with licensing board to verify credits can be claimed in your state.

Participant Requirement and Statement of Credit: To receive credit, participants must fully attend each session (no partial credit will be awarded), pass in a completed attendance verification form, and using the access code provided, complete the online evaluation for each session attended. Attendance will be verified. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their future educational needs.

Pharmacists: CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant's NABP account within 72 hours where an official certificate of credit can be printed. Evaluations must be completed within 60 days of program date to receive credit. Starting January 1, 2018 ACPE will be charging a \$200 fee for any credits submitted into the CPE Monitor after 60 days. It is the participant's responsibility to complete all activity evaluations and confirm that credits are in the CPE Monitor after attending an activity.

Statement of Disclosure: Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with any commercial interest as well as any commercial support received for this conference.

Refund Policy: A full refund will be provided only if a written request is received by American Health Resources, Inc. at least 48 hours prior to the program or if the program is cancelled. American Health Resources, Inc. reserves the right to change the presenters, topics or seminar schedules. If the program is cancelled, American Health Resources, Inc. reserves the right to change the presenters, topics or seminar schedules.

American Health Resources, Inc.
130 Liberty St., Suite 13A
Brockton, MA 02301

PRST STD
U.S. Postage
PAID
CCP&DF
02571
Permit 3



**11th Northeast Regional
Hematology/Oncology
Pharmacists Symposium**

October 13 & 14, 2017

Boston Marriott Burlington

*This programming has been designed to meet the educational needs
of pharmacists, nurses and other interested healthcare professionals
specializing in hematology/oncology practice*



Like us on Facebook!

<http://www.facebook.com/pages/American-Health-Resources-Inc/347292468615650>